Skip to content

The Effect of Training on Endothelial Function, Progression of Disease,Inflammation, Heart Rate Variability and Mental Health After Percutaneous Coronary Intervention

Effect of Exercise Training After Percutaneous Coronary Intervention

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00469950
Acronym
EFECTOR
Enrollment
40
Registered
2007-05-07
Start date
2006-01-31
Completion date
2009-02-28
Last updated
2015-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

PCI, stent, training, endothelial function, restenosis, late luminal loss, heart rate variability, oxygen uptake capacity, inflammatory markers

Brief summary

The Efector study is an open, randomized and controlled trial assessing the effect of regular exercise training on endothelial function, inflammatory markers, progression of disease, heart rate variability and mental health in patients who have been successfully treated with percutaneous coronary intervention and stent implantation for angina pectoris.

Detailed description

Pas er randomized to a 6 months training group or none training. At baseline and at 6 months patients are examined with blood tests to measure serum concentrations of inflammatory markers, a test for endothelial function, heart rate variability and a coronary angiogram. Further patients are asked to answer questionnaires concerning mental health (SF36, HADS).

Interventions

BEHAVIORALexercise training

Exercise training in groups

Sponsors

Helse Stavanger HF
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Successful PCI with stent implantation, * Able to participate in the training program, * No planned further revascularisation

Exclusion criteria

* CAGB, * Inflammatory diseases other than CAD, * Heart failure, * Severe kidney failure, * Inability to participate in the training program

Design outcomes

Primary

MeasureTime frame
flow mediated dilation, serum concentrations of biomarkers, restenosis-rate/ late luminal loss, heart rate variability in SDNN6 months

Secondary

MeasureTime frame
Oxygen uptake capacity (mg/kg/min), Sf36 scores6 months

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026